首页> 外文期刊>Frontiers in Pediatrics >Emerging Biomarkers for Prediction and Early Diagnosis of Necrotizing Enterocolitis in the Era of Metabolomics and Proteomics
【24h】

Emerging Biomarkers for Prediction and Early Diagnosis of Necrotizing Enterocolitis in the Era of Metabolomics and Proteomics

机译:新兴生物标志物,用于在代谢组和蛋白质组学时代中坏死性肠结肠炎的预测和早期诊断

获取原文
           

摘要

Necrotizing Enterocolitis (NEC) is a catastrophic disease affecting predominantly premature infants and is characterized by high mortality and serious long-term consequences. Traditionally, diagnosis of NEC is based on clinical and radiological findings, which, however, are non-specific for NEC, thus confusing differential diagnosis of other conditions such as neonatal sepsis and spontaneous intestinal perforation. In addition, by the time clinical and radiological findings become apparent, NEC has already progressed to an advanced stage. During the last three decades, a lot of research has focused on the discovery of biomarkers, which could accurately predict and make an early diagnosis of NEC. Biomarkers used thus far in clinical practice include acute phase proteins, inflammation mediators, and molecules involved in the immune response. However, none has been proven accurate enough to predict and make an early diagnosis of NEC or discriminate clinical from surgical NEC or other non-NEC gastrointestinal diseases. Complexity of mechanisms involved in NEC pathogenesis, which remains largely poorly elucidated, could partly explain the unsatisfactory diagnostic performance of the existing NEC biomarkers. More recently applied technics can provide important insight into the pathophysiological mechanisms underlying NEC but can also aid the detection of potentially predictive, early diagnostic, and prognostic biomarkers. Progress in omics technology has allowed for the simultaneous measurement of a large number of proteins, metabolic products, lipids, and genes, using serum/plasma, urine, feces, tissues, and other biological specimens. This review is an update of current data on emerging NEC biomarkers detected using proteomics and metabolomics, further discussing limitations and future perspectives in prediction and early diagnosis of NEC.
机译:坏死性小肠结肠炎(NEC)是一种影响主要过早婴儿的灾难性疾病,其特征在于死亡率和严重的长期后果。传统上,NEC的诊断基于临床和放射学发现,然而,NEC是非特异性的,因此混淆了新生儿脓毒症和自发肠道穿孔等其他条件的差异诊断。此外,当时临床和放射发现变得明显,NEC已经进入了高级阶段。在过去的三十年中,大量研究专注于发现生物标志物,这可以准确地预测并提前诊断NEC。迄今为止临床实践的生物标志物包括急性期蛋白,炎症介质和参与免疫应答的分子。然而,没有足够的准确证明可以预测和从外科NEC或其他非NEC胃肠疾病中诊断NEC或鉴别临床。涉及NEC发病机制的机制的复杂性仍然很大程度上阐明,可以部分解释现有NEC生物标志物的不令人满意的诊断性能。最近应用的技术可以对NEC的潜在病理生理机制提供重要的洞察,但也可以帮助检测潜在预测性,早期诊断和预后生物标志物。 OMICS技术的进展已经允许使用血清/血浆,尿液,粪便,组织和其他生物标本来同时测量大量蛋白质,代谢产物,脂质和基因。该审查是使用蛋白质组学和代谢组织检测到的新兴NEC生物标志物的当前数据的更新,进一步讨论了在NEC预测和早期诊断中的局限和未来的视角。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号